Literature DB >> 24267914

Vemurafenib significantly decreases glomerular filtration rate.

C Uthurriague1, S Thellier, D Ribes, L Rostaing, C Paul, N Meyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24267914     DOI： 10.1111/jdv.12322

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  7 in total

Review 1.  Renal Toxicities of Targeted Therapies.

Authors:  Anum Abbas; Mohsin M Mirza; Apar Kishor Ganti; Ketki Tendulkar
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

2.  Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Authors:  N Kramkimel; A Thomas-Schoemann; L Sakji; Jl Golmard; G Noe; E Regnier-Rosencher; N Chapuis; E Maubec; M Vidal; Mf Avril; F Goldwasser; L Mortier; N Dupin; B Blanchet
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

3.  Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.

Authors:  Yuntao Bai; Ji Young Kim; Bijay Bisunke; Laura A Jayne; Josie A Silvaroli; Michael S Balzer; Megha Gandhi; Kevin M Huang; Veronika Sander; Jason Prosek; Rachel E Cianciolo; Sharyn D Baker; Alex Sparreboom; Kenar D Jhaveri; Katalin Susztak; Amandeep Bajwa; Navjot Singh Pabla
Journal:  Kidney Int       Date:  2021-09-15       Impact factor: 18.998

Review 4.  Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

Authors:  Rimda Wanchoo; Ala Abudayyeh; Mona Doshi; Amaka Edeani; Ilya G Glezerman; Divya Monga; Mitchell Rosner; Kenar D Jhaveri
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-21       Impact factor: 8.237

Review 5.  Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network.

Authors:  Rimda Wanchoo; Kenar D Jhaveri; Gilbert Deray; Vincent Launay-Vacher
Journal:  Clin Kidney J       Date:  2016-01-18

Review 6.  Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.

Authors:  Kenar D Jhaveri; Rimda Wanchoo; Vipulbhai Sakhiya; Daniel W Ross; Steven Fishbane
Journal:  Kidney Int Rep       Date:  2016-09-21

7.  Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma.

Authors:  Charlotte Hurabielle; Evangéline Pillebout; Thomas Stehlé; Cécile Pagès; Jennifer Roux; Pierre Schneider; Sylvie Chevret; Cendrine Chaffaut; Anne Boutten; Samia Mourah; Nicole Basset-Seguin; Emmanuelle Vidal-Petiot; Céleste Lebbé; Martin Flamant
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.